Large inefficiency from 250 to about 300. Series of higher lowz despite ugly earnings and outlook. Think of it this way: In march and height of pandemic the worst was probably priced in. IMO more meat on the bone in terms of upside. Its a patient setup but upside is there.
Komen:
Following the plan so far